Naptumomab estafenatox
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Mouse |
| Target | 5T4 |
| Identifiers | |
| CAS Number | 676258-98-3  |
| ATC code | none |
| UNII | 93T929W6LC |
| Chemical data | |
| Formula | C3255H5025N855O1050S18 |
| Molecular mass | 73.5 kg/mol |
 (what is this?) (verify) |
|
Naptumomab estafenatox (ABR-217620) is a drug being developed for the treatment of various types of cancer like non-small cell lung carcinoma[1] and renal cell carcinoma.[2]
Mechanism of action
Chemically, it is a fusion protein consisting of the antigen-binding fragment (Fab) of a monoclonal antibody with the superantigen staphylococcal enterotoxin A (SEA/E-120, "estafenatox").[3] The Fab binds to 5T4, an antigen expressed by various tumor cells, and the superantigen induces an immune response by activating T lymphocytes.
See also
- Nacolomab tafenatox, a drug with a similar chemical structure and mechanism
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ ClinicalTrials.gov
- ↑ WHO Drug Information
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibodies for tumors
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
